---
id: 236
title: Influenza
category: clinical_syndromes
subcategory: viral
tags: [influenza, flu, oseltamivir, neuraminidase-inhibitor, vaccination]
difficulty: easy
---

## Question

How is influenza managed? Use **"Oseltamivir 75mg BID × 5d (Within 48h), Vaccinate Annually"** framework.

## Answer

### **Etiology:**

**Influenza Viruses:**
- **Type A** (most common, epidemics/pandemics, H1N1, H3N2)
- **Type B** (seasonal epidemics, milder)
- **Type C** (mild illness, uncommon)
- **Type D** (primarily cattle, not humans)

### **Clinical Presentation:**

**Classic:**
- **Abrupt onset** (unlike common cold)
- **Fever, chills** (>90%)
- **Cough** (dry, non-productive initially)
- **Severe myalgias, arthralgias** ("body aches")
- **Headache**
- **Fatigue** (can last weeks)
- **Sore throat, rhinorrhea** (less prominent than cold)

**Differentiation from Common Cold:**
- **Influenza:** Abrupt onset, high fever, severe myalgias
- **Common cold:** Gradual onset, low-grade fever, prominent rhinorrhea

### **Diagnosis:**

**Clinical Diagnosis:**
- **During flu season** + **classic symptoms** → presumptive diagnosis

**Laboratory Testing (Selective Use):**

**Rapid Influenza Diagnostic Tests (RIDTs):**
- **Result in 10-15 minutes**
- **Low sensitivity** (50-70%), high specificity (90-95%)
- **Negative DOES NOT rule out** influenza

**Molecular Tests (PCR, NAAT):**
- **Gold standard** (sensitivity >95%)
- **Detects influenza A/B, can subtype**
- **Result in 1-8 hours**

**Indications for Testing:**
- **Hospitalized patients** (guides treatment, infection control)
- **Severe illness** (consider antiviral regardless of testing)
- **Immunocompromised**
- **Uncertain diagnosis**
- **Outbreak investigation**

**Do NOT Test:**
- **Mild outpatient illness during flu season** (treat empirically if indicated)

### **Treatment:**

**Antiviral Therapy (Neuraminidase Inhibitors):**

**Indications:**
- **Severe illness** (hospitalized, pneumonia, hypoxemia)
- **High-risk patients** (see below)
- **Within 48h of symptom onset** (most benefit, but can give >48h if severe/hospitalized)

**High-Risk Groups:**
- **Age <2y or ≥65y**
- **Pregnancy or <2 weeks postpartum**
- **Chronic conditions** (lung, heart, kidney, liver disease, diabetes, immunosuppression)
- **Obesity** (BMI ≥40)
- **Nursing home residents**

**First-Line:**
- **Oseltamivir (Tamiflu) 75mg PO BID × 5 days**
  - **Children:** Weight-based dosing
  - **Reduces symptom duration by ~1 day** (if started within 48h)
  - **Reduces complications** (pneumonia, hospitalization)

**Alternatives:**
- **Baloxavir marboxil (Xofluza) 40mg PO × 1** (single dose)
  - **If ≥80 kg:** 80mg × 1
  - **Inhibits cap-dependent endonuclease** (different mechanism than neuraminidase inhibitors)
  - **Rapid viral clearance**, but **resistance** can emerge (especially influenza A/H3N2)
- **Zanamivir (Relenza) 10mg inhaled BID × 5 days**
  - **Avoid if reactive airway disease** (bronchospasm risk)
- **Peramivir 600mg IV × 1** (single dose)
  - **If cannot take PO**

**Hospitalized/Severe:**
- **Oseltamivir 75mg PO BID** × 5 days **(or longer if immunocompromised, persistent viral shedding)**
- **Double dose** (150mg BID) if severely immunocompromised, critically ill

**Do NOT Use:**
- **Adamantanes** (amantadine, rimantadine) - widespread resistance (>99% of circulating strains)

### **Complications:**

**Primary Influenza Pneumonia:**
- **Viral pneumonia** (diffuse bilateral infiltrates, hypoxemia, ARDS)
- **High mortality**

**Secondary Bacterial Pneumonia:**
- ***S. aureus* (including MRSA), *S. pneumoniae*, *H. influenzae***
- **Presents days after initial improvement** ("biphasic illness")
- **New fever, productive cough, infiltrate on CXR**

**Other Complications:**
- **Myositis** (rhabdomyolysis, especially children)
- **Myocarditis, pericarditis**
- **Encephalopathy** (rare)
- **Guillain-Barré syndrome** (post-infection)
- **Exacerbation of chronic conditions** (COPD, asthma, CHF)

### **Chemoprophylaxis:**

**Indications (Post-Exposure):**
- **High-risk patients** exposed to confirmed influenza (household, healthcare)
- **Immunocompromised** (poor vaccine response)
- **Unvaccinated healthcare workers** (during outbreak)

**Regimen:**
- **Oseltamivir 75mg PO daily × 7-10 days** (duration of exposure)
- **Start within 48h of exposure**

**NOT a Substitute for Vaccination:**
- **Annual vaccination remains primary prevention**

### **Prevention (Vaccination):**

**Annual Influenza Vaccine:**
- **Recommended for ALL ≥6 months** (universal vaccination)
- **Best given October-November** (before flu season)

**Types:**
- **Inactivated influenza vaccine (IIV):** IM (preferred for most)
- **Live attenuated influenza vaccine (LAIV):** Intranasal (ages 2-49y, not if immunocompromised, pregnancy, asthma)
- **Recombinant vaccine:** IM (egg-free, for egg allergy)
- **High-dose vaccine:** For ≥65y (better immune response)

**Contraindications:**
- **Severe egg allergy** (with systemic reaction) - use recombinant vaccine
- **Prior severe reaction to vaccine**

### **Prognosis:**

**Uncomplicated:**
- **Self-limited** (3-7 days)
- **Fatigue may persist weeks**

**Mortality:**
- **Seasonal influenza:** 12,000-52,000 deaths/year (US)
- **Higher in:** Elderly, infants, pregnant, chronic disease

## Key Points

### **Oseltamivir 75mg BID × 5 Days:**
- **Within 48h** of symptom onset (most benefit)
- **Can give >48h** if severe, hospitalized

### **Treat if Severe OR High-Risk:**
- **Severe:** Hospitalized, pneumonia, hypoxemia
- **High-risk:** Age <2y or ≥65y, pregnancy, chronic conditions, immunocompromised

### **Reduces Symptom Duration ~1 Day:**
- **Reduces complications** (pneumonia, hospitalization)

### **Annual Vaccination = Primary Prevention:**
- **All ≥6 months** (universal recommendation)
- **October-November** (before flu season)

### **Secondary Bacterial Pneumonia:**
- ***S. aureus*, *S. pneumoniae*** (days after initial improvement)
- **Biphasic illness** (improve → worsen)

### **Clinical Pearls:**
- **Oseltamivir 75mg BID × 5 days** (within 48h, or >48h if severe/hospitalized)
- **Treat if:** Severe illness OR high-risk (age <2y or ≥65y, pregnancy, chronic disease)
- **Annual vaccination** (all ≥6 months, October-November)
- **Secondary bacterial pneumonia:** *S. aureus*, *S. pneumoniae* (biphasic illness)
- **Baloxavir:** Single-dose alternative (but resistance risk)
- **Do NOT use adamantanes** (widespread resistance)

## Sources

- [CDC: Influenza Antiviral Treatment Guidelines 2024]
- [IDSA: Influenza Management 2024]

## Media

N/A
